Abbott secures expanded FDA approval for Infinity DBS System

27 January 2020 (Last Updated January 27th, 2020 12:06)

Medical devices maker Abbott Laboratories has secured approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system to treat Parkinson’s disease.

Abbott secures expanded FDA approval for Infinity DBS System
Abbott has received expanded FDA approval for its new Infinity DBS System. Credit: Abbott.

Medical devices maker Abbott Laboratories has secured approval from the US Food and Drug Administration (FDA) for its Infinity Deep Brain Stimulation (DBS) system to treat Parkinson’s disease.

The DBS system will allow targeting of a specific area of the brain known as the internal globus pallidus (GPi).

GPi is critical to the motor function. DBS system can target GPi to improve the symptoms of Parkinson’s disease not controlled by medication.

University of Minnesota Udall centre of excellence for Parkinson’s research and neurology department head Dr Jerrold Vitek said: “The internal segment of the global pallidus, or GPi, is a well-established valuable DBS target for the management of the motor signs associated with Parkinson’s disease, and is a preferred target for many patients, particularly for those with troublesome medication-induced dyskinesia.

“This approval expands the options for patients to tailor treatment to their unique needs, with the added benefits of being able to target precise areas and utilizing a patient-friendly iOS device.”

Directional leads for the Infinity DBS system approved for treating movement disorders include Parkinson’s disease and Essential Tremor, Subthalamic nucleus (STN), ventral intermediate nucleus (VIM) and GPi.

Additionally, the Informity feature will allow doctors to modernise the programming process with an iPad, while patients can manage their symptoms using Infinity DBS System iPod touch controller.

DBS system, built to offer directed stimulation to the areas of the brain, optimises patient outcomes and limits side effects.

Abbott neuromodulation business medical affairs director Binith Cheeran said: “Abbott’s PROGRESS study has led the way in establishing the value of directional DBS systems for targeted areas of the brain.

“The approval of Abbott’s Infinity DBS system with targeted stimulation is a significant advancement for people living with Parkinson’s disease and their care teams. The ability to optimise the programming for each individual opens the door for a new standard of care for DBS therapy.”

Recently, Abbott received approval from the US Food and Drug Administration (FDA) for its less-invasive heart pump implant procedure to help patients avoid open-heart surgery.